PDCD1 and melanoma: The four-year-long “Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients (NCT03197636)” trial in Denmark combined PDL therapy for advanced melanoma in combination of vitamin D. This trial ended in 2022 and no study results are available yet.